Publications by authors named "P Orcel"
Article Synopsis
- Fibrodysplasia ossificans progressiva (FOP) is a rare disorder causing painful flare-ups and abnormal bone growth, known as heterotopic ossification (HO).
- In a clinical trial, patients receiving the anti-activin A antibody garetosmab experienced fewer severe and lengthy flare-ups compared to those given a placebo, leading to a notable difference in quality of life.
- The study found that 71% of placebo patients had flare-ups linked to new HO lesions, while garetosmab reduced the severity, duration, and frequency of these flare-ups throughout the trial.
Background: There are several therapeutic options for the management of shoulder adhesive capsulitis (AC). The superiority of arthro-distension over intra-articular steroid injection (ISI) for AC remains controversial.
Objectives: To evaluate the efficacy of a single arthro-distension procedure combined with early and intensive mobilization (ADM) and physiotherapy, versus ISI and physiotherapy, in people with AC lasting ≥3 months.
Article Synopsis
- Slow-flow vascular malformations often have mutations in the PI3K/AKT/mTOR pathway, prompting the need for effective drug therapies like sirolimus, which has shown promise in prior trials.
- The VASE trial is a large-scale, ongoing phase III study initiated in 2016, assessing the efficacy and safety of sirolimus over 2 years in both pediatric and adult patients with these conditions.
- Preliminary results show that 85% of patients experienced clinical improvement, with some adverse effects reported; however, many patients experienced a recurrence of symptoms after treatment ended.
Article Synopsis
- - Fibrodysplasia ossificans progressiva (FOP) is a rare condition that causes painful heterotopic ossification in connective tissues, leading to disability.
- - In the LUMINA-1 phase 2 trial, adults with FOP were given either garetosmab (an activin A-blocking antibody) or a placebo over two 28-week periods, focusing on safety and effects on HO lesions.
- - Although the primary efficacy endpoint was not met in the first period, garetosmab significantly reduced the development of new HO lesions in the second period compared to placebo, with ongoing investigations into its effectiveness.
Economic impact of work disability due to chronic low back pain from the patient perspective.
Rev Epidemiol Sante Publique
August 2023
Objectives: Low back pain (LBP) is one of the main expenditure items for health systems. Data on the economic impact of LBP are uncommon from the patient perspective. The aim of this study was to estimate the economic impact of work disability related to chronic LBP from the patient perspective.
View Article and Find Full Text PDF